Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Lexaria Bioscience Corporation LEXX

Alternate Symbol(s):  LEXXW

Biotechnology
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LEXX)

Lexaria Releases Annual Letter from the CEO

ACCESS Newswire 1 day ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

ACCESS Newswire December 30, 2025

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

ACCESS Newswire December 23, 2025

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ACCESS Newswire December 16, 2025

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ACCESS Newswire December 15, 2025

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

ACCESS Newswire November 12, 2025

Lexaria Bioscience Corp. Provides Strategic Update

ACCESS Newswire October 9, 2025

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ACCESS Newswire September 29, 2025

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ACCESS Newswire September 26, 2025
View More News ››

Opinion & Analysis (NDAQ:LEXX)

Could DehydraTECH CBD be Worth $3 Billion a Year to Lexaria?

Featured Submission March 10, 2021

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

Stockhouse Editorial December 2, 2020

VIDEO: Technology for Healthier Ingestion of Drugs & Molecules

BTV-Business Television March 26, 2019

VIDEO: Ingesting Instead of Inhaling Could Save 60,000 Lives a Year

BTV-Business Television March 5, 2019

Capitalizing on the growing need of a merchant bank for global medical cannabis companies

Stockhouse Editorial September 25, 2018

The S-Curve Reveals It Is Early Days in the Marijuana Growth Cycle

Streetwise Reports February 14, 2018
View More Opinion ››

Bullboard Posts (NDAQ:LEXX)

RE:hey ranman

ranman john remember, i wanred ya STOP following fake gurus!
waketfup - 13 days ago

Zacks $6 valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_10022025_LEXX_Vandermosten.pdf
lscfa - December 23, 2025

50% less side effects than Rybelsus

https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/primary-endpoint-successfully-achieved-in-lexarias-phase-1b-study...
lscfa - December 23, 2025

Material Transfer Agreement Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended   ...
lscfa - November 12, 2025

RE:RE:LEXX....all that volume & minor Price Action was for 1 thing

U can have as many shares u want at market for less than 1.3 or 1.5.  If you were at rhat deal u are under water now.
juansito - September 28, 2025

RE:LEXX....all that volume & minor Price Action was for 1 thing

100%. They really have no respect for shareholders. They should have offered us some lube before ramming that one in. I didn't get...
ranman - September 26, 2025
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc., an oil and natural gas company, engages in the acquisition, development, exploration, and production ...
View More »

Podcasts